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Abstract
Background: As gene expression signatures may serve as biomarkers, there is a need to develop
technologies based on mRNA expression patterns that are adaptable for translational research.
Xceed Molecular has recently developed a Ziplex® technology, that can assay for gene expression
of a discrete number of genes as a focused array. The present study has evaluated the
reproducibility of the Ziplex system as applied to ovarian cancer research of genes shown to exhibit
distinct expression profiles initially assessed by Affymetrix GeneChip® analyses.
Methods: The new chemiluminescence-based Ziplex® gene expression array technology was
evaluated for the expression of 93 genes selected based on their Affymetrix GeneChip® profiles as
applied to ovarian cancer research. Probe design was based on the Affymetrix target sequence that
favors the 3' UTR of transcripts in order to maximize reproducibility across platforms. Gene
expression analysis was performed using the Ziplex Automated Workstation. Statistical analyses
were performed to evaluate reproducibility of both the magnitude of expression and differences
between normal and tumor samples by correlation analyses, fold change differences and statistical
significance testing.
Results: Expressions of 82 of 93 (88.2%) genes were highly correlated (p < 0.01) in a comparison
of the two platforms. Overall, 75 of 93 (80.6%) genes exhibited consistent results in normal versus
tumor tissue comparisons for both platforms (p < 0.001). The fold change differences were
concordant for 87 of 93 (94%) genes, where there was agreement between the platforms regarding
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statistical significance for 71 (76%) of 87 genes. There was a strong agreement between the two
platforms as shown by comparisons of log2 fold differences of gene expression between tumor
versus normal samples (R = 0.93) and by Bland-Altman analysis, where greater than 90% of
expression values fell within the 95% limits of agreement.
Conclusion: Overall concordance of gene expression patterns based on correlations, statistical
significance between tumor and normal ovary data, and fold changes was consistent between the
Ziplex and Affymetrix platforms. The reproducibility and ease-of-use of the technology suggests
that the Ziplex array is a suitable platform for translational research.
Background
During the last decade, the advent of high-throughput
techniques such as DNA microarrays, has allowed investi-
gators to interrogate the expression level of thousands of
genes concurrently. Due to the heterogeneous nature of
many cancers in terms of both their genetic and molecular
origins and their response to treatment, individualizing
patient treatment based on the expression levels of signa-
ture genes may impact favorably on patient management
[1,2]. In ovarian cancer, discrete gene signatures have
been determined from microarray analysis of ovarian can-
cer versus normal ovarian tissue [3-6], correlating gene
expression profiles to survival or prognosis [7,8], studies
of chemotherapy resistance [9,10], and functional studies
such as chromosome transfer experiments [11,12]. Recent
studies have focused on a biomarker approach [13], with
specific prognostic markers being discovered by relating
gene expression profiles to clinical variables [14-16]. In
addition, there is a trend towards offering patient-tailored
therapy, where expression profiles are related to key clini-
cal features such as TP53 or HER2 status, surgical outcome
and chemotherapy resistance [1,17].
A major challenge in translating promising mRNA-based
expression biomarkers has been the reproducibility of
results when adapting gene expression assays to alterna-
tive platforms that are specifically developed for clinical
laboratories. Xceed Molecular has recently developed a
multiplex gene expression assay technology termed the
Ziplex® Automated Workstation, designed to facilitate the
expression analysis of a discrete number of genes (up to
120) specifically intended for clinical translational labora-
tories. The Ziplex array is essentially a three-dimensional
array comprised of a microporous silicon matrix contain-
ing oligonucleotides probes mounted on a plastic tube.
The probes are designed to overlap the target sequences of
the probes used in large-scale gene expression array plat-
forms from which the expression signature of interest was
initially detected, such as the 3' UTR target sequences of
the Affymetrix GeneChip®. However unlike most large-
scale expression platforms, gene expression detection is by
chemiluminescence. Recently, the Ziplex technology was
compared to five other commercially available and well
established gene expression profiling systems following
the methods introduced by the MicroArray Quality Con-
trol (MAQC) consortium [18-20] and reported in a white
paper by Xceed Molecular [21]. The original MAQC study
(MAQC Consortium, 2006) was undertaken because of
concerns about the reproducibility and cross-platform
concordance between gene expression profiling plat-
forms, such as microarrays and alternative quantitative
platforms. By assessing the expression levels of the MAQC
panel of 53 genes on universal RNA samples, it was deter-
mined that the reproducibility, repeatability and sensitiv-
ity of the Ziplex system were at least equivalent to that of
other MAQC platforms [21].
There is a need to implement reliable gene expression
technologies that are readily adaptable to clinical labora-
tories in order to screen individual or multiple gene
expression profiles ("signature") identified by large-scale
gene expression assays of cancer samples. Our ovarian
cancer research group (as well as other independent
groups) has identified specific gene expression profiles
from mining Affymetrix GeneChip expression data illus-
trating the utility of this approach at identifying gene sig-
nature patterns associated with specific parameters of the
disease [14,22]. Ovarian cancer specimens are typically
large and exhibit less tumor heterogeneity and thus may
be amenable to gene expression profiling in a reproduci-
ble way. However, until recently the gene expression tech-
nologies available that could easily be adapted to a
clinical setting have been limited primarily by the exper-
tise required to operate them. The recently developed
Ziplex Automated Workstation offers a opportunity to
develop RNA expression-based biomarkers that could
readily be adapted to clinical settings as the 'all-in-one'
technology appears to be relatively easy to use. However,
this system has not been applied to ovarian cancer disease
nor has its use been reported in human systems. In the
present study we have evaluated the reproducibility of the
Ziplex system using 93 genes, selected based on their
expression profile as initially assessed by Affymetrix Gene-
Chip microarray analyses from a number of ovarian can-
cer research studies from our group [6,14,22-26]. These
include genes which are highly differentially expressed
between ovarian tumor samples and normal ovary sam-
ples that were identified using both newer and older gen-Journal of Translational Medicine 2009, 7:55 http://www.translational-medicine.com/content/7/1/55
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eration GeneChips [6,22,25,26]. In addition, to address
the question of sensitivity, genes known to have a wide
range of expression values were tested some of which
show comparable values of expression between represent-
ative normal and ovarian tumor tissue samples but repre-
sent a broad range of expression values [25,26]. Other
genes known to be relevant to ovarian cancer including
tumor suppressor genes and oncogenes were included in
the analysis. Selected highly differentially expressed genes
from an independent microarray analysis of ovarian
tumors compared to short term cultures of normal epithe-
lial cells was also included [3]. In many cases, the level of
gene expression identified by Affymetrix GeneChip analy-
sis was independently validated by semi-quantitative RT-
PCR, real-time RT-PCR, or Northern Blot analysis
[6,14,22,24-26]. Expression assays were performed using
RNA from serous ovarian tumors, short term cultures of
normal ovarian surface epithelial cells, and four well char-
acterized ovarian cancer cell lines which were selected
based on their known expression profiles using Affymetrix
microarray analyses. Comparisons were made between
the Ziplex system and expression profiles generated using
the U133A Affymetrix GeneChip platform. An important
aspect of this study was that gene expression profiling of
Ziplex system was performed in a blinded fashion where
the sample content was not known to the immediate
users. It is envisaged that both the nature of the candidates
chosen and their range of gene expression will permit for
a direct comment on the sensitivity, reproducibility and
overall utility of the Ziplex array as a platform for gene
expression array analysis for translational research.
Methods
Source of RNA
Total RNA was extracted with TRIzol reagent (Gibco/BRL,
Life Technologies Inc., Grand Island, NY) from primary
cultures of normal ovarian surface epithelial (NOSE) cells,
frozen malignant serous ovarian tumor (TOV) samples
and epithelial ovarian cancer (EOC) cell lines as described
previously [27]. Additional File 1 provides a description
of samples used in the expression analyses.
The NOSE and TOV samples were attained from the study
participants at the Centre de recherche du Centre hospi-
talier de l'Université de Montréal – Hôpital Hotel-Dieu
and Institut du cancer de Montréal with signed informed
consent as part of the tissue and clinical banking activities
of the Banque de tissus et de données of the Réseau de
recherche sur le cancer of the Fonds de la Recherche en
Santé du Québec (FRSQ). The study was granted ethical
approval from the Research Ethics Boards of the partici-
pating research institutes.
Ziplex array and probe design
The 93 genes used for assessing the reproducibility of the
Ziplex array are shown in Table 1. The criteria for gene
selection were: genes exhibiting statistically significant
differential expression between NOSE and TOV samples
as assessed by Affymetrix U133A microarray analysis;
genes exhibiting a range of expression values (nominally
low, medium or high) based on Affymetrix U133A micro-
array analysis, in order to assess sensitivity; genes exhibit-
ing differential expression profiles based on older
generation Affymetrix GeneChips (Hs 6000 [6] and Hu
6800 [23]); and genes known or suspected to play a role
in ovarian cancer (Table 1). Initial selection criteria for
genes in their original study included individual two-way
comparisons [25,26], fold-differences [6,23], and fold
change analysis using SAM (Significance Analysis of
Microarrays) [3] between TOV and NOSE groups. Some
genes were selected based on their low, mid or high range
of expression values that did not necessarily exhibit statis-
tically significant differences between TOV and NOSE
groups.
The Ziplex array or TipChip is a three-dimensional array
comprised of a microporous silicon matrix containing oli-
gonucleotide probes that is mounted on a plastic tube.
Each probe was spotted in triplicate. In order to replicate
gene expression assays derived from the Affymetrix Gene-
Chip analysis, probe set design was based on the Affyme-
trix U133A probe set target sequences for the selected gene
(refer to Table 1). Gene names were assigned using Uni-
Gene ID Build 215 (17 August 2008). To improve accu-
racy of probe design, and to account for variation of probe
hybridization, up to three probes were designed for each
gene. From this exercise, a single probe was chosen to pro-
vide the most reliable and consistent quantification of
gene expression. Gene accession numbers corresponding
to the Affymetrix probe set sequences for each gene were
verified by BLAST alignment searches of the NCBI Tran-
script Reference Sequences (RefSeq) database http://
www.ncbi.nlm.nih.gov/projects/RefSeq/. Array Designer
(Premier Biosoft, Palo Alto, CA) was used to generate
three probes from each verified RefSeq transcript that were
between 35 to 50 bases in length (median 46 base pairs),
exhibited a melting temperature of approximately 70°C,
represent a maximum distance of 1,500 base pairs from
the from 3' end of the transcript, and exhibited minimal
homology to non-target RefSeq sequences. Using this
approach it was possible to design three probes for 92 of
the 93 selected genes: APOE was represented by only two
probes. For the 93 genes analyzed, the median distance
from the 3' end was 263 bases, whereas less than 12% of
the probes were more than 600 bases from the 3' end. Ten
probes were also designed for genes that were not
expected to vary significantly between TOV and NOSE
samples based on approximately equal expression in the
two sample types and relatively low coefficients of varia-
tion (18 to 20%) as assessed by Affymetrix U133A micro-
array analysis of the samples; such probes were potential
normalization controls. Based on standard quality controlJournal of Translational Medicine 2009, 7:55 http://www.translational-medicine.com/content/7/1/55
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Table 1: Selection Criteria of Genes Assayed by Ziplex Technology
Selection Criteria Categories Affymetrix U133A Probe Set GeneID* Gene Name Reference
A: Differentially expressed genes based on Affymetrix 
U133A analysis
208782_at 11167 FSTL1 25
213069_at 57493 HEG1 25
218729_at 56925 LXN 25
202620_s_at 5352 PLOD2 25
217811_at 51714 SELT 25
213338_at 25907 TMEM158 25
203282_at 2632 GBE1 25
204846_at 1356 CP 25
221884_at 2122 EVI1 25
202310_s_at 1277 COL1A1 26
201508_at 3487 IGFBP4 26
200654_at 5034 P4HB 26
212372_at 4628 MYH10 26
216598_s_at 6347 CCL2 26
208626_s_at 10493 VAT1 26
41220_at 10801 SEPT9 26
208789_at 284119 PTRF 26
206295_at 3606 IL18 22
202859_x_at 3576 IL8 22
209969_s_at 6772 STAT1 22
209846_s_at 11118 BTN3A2 22
220327_at 389136 VGLL3 11
203180_at 220 ALDH1A3 26
204338_s_at 5999 RGS4 26
204879_at 10630 PDPN 26
207510_at 623 BDKRB1 26
208131_s_at 5740 PTGIS 26
211430_s_at 3500 IGHG1 26
216834_at 5996 RGS1 26
266_s_at 100133941 CD24 26
213994_s_at 10418 SPON1 26
221671_x_at 3514 IGKC 26
B: Genes exhibiting a range of expression values based on 
Affymetrix U133A analysis
218304_s_at 114885 OSBPL11 25
219295_s_at 26577 PCOLCE2 25
205329_s_at 8723 SNX4 25
219036_at 80321 CEP70 25
218926_at 55892 MYNN 25
208836_at 483 ATP1B3 25
204992_s_at 5217 PFN2 25
214143_x_at 6152 RPL24 25
208691_at 7037 TFRC 25
203002_at 51421 AMOTL2 25
221492_s_at 64422 ATG3 25
218286_s_at 9616 RNF7 25
212058_at 23350 SR140 25
201519_at 9868 TOMM70A 25
209933_s_at 11314 CD300A 26
219184_x_at 29928 TIMM22 26
204683_at 3384 ICAM2 26
212529_at 124801 LSM12 26
211899_s_at 9618 TRAF4 26
218014_at 79902 NUP85 26
200816_s_at 5048 PAFAH1B1 26
202395_at 4905 NSF 26
201388_at 5709 PSMD3 26
220975_s_at 114897 C1QTNF1 26
210561_s_at 26118 WSB1 26
202856_s_at 9123 SLC16A3 26Journal of Translational Medicine 2009, 7:55 http://www.translational-medicine.com/content/7/1/55
Page 5 of 14
(page number not for citation purposes)
measures of the manufacturer, three probes representing
ACTB, GAPDH, and UBC and a set of standard control
probes, including a set of 5' end biased probes for RPL4,
POLR2A, ACTB, GAPDH and ACADVL were printed on
each array for data normalization and quality assessment.
The probes were printed on two separate TipChip arrays.
Hybridization and raw data collection
Total RNA from NOSE and TOV samples and the four
EOC cell lines were prepared as described above and pro-
vided to Xceed Molecular for hybridization and data col-
lection in a blinded manner. RNA quality (RNA integrity
number (RIN)) using the Agilent 2100 Bioanalyzer Nano,
total RNA assay was assessed for each sample (Additional
File 1). For each sample, approximately 500 ng of RNA
was amplified and labeled with the Illumina® TotalPrep™
RNA Amplification Kit (Ambion, Applied Biosystems
Canada, Streetsville, ON, CANADA). Although sample
MG0026 (TOV-1150G) had a low RIN number, it was car-
ried through the study. Sample MG0001 (TOV-21G) had
no detectable RIN number and MG0013 (NOV-1181)
failed to produce amplified RNA. Neither of these samples
were carried through the study. Five μg of the resulting
biotin-labeled amplified RNA was hybridized on each
TipChip. The target molecules were biotin labeled, and an
HRP-streptavidin complex was used for imaging of bound
targets by chemiluminescence. Hybridization, washing,
chemiluminescent imaging and data collection were auto-
matically performed by the Ziplex Workstation (Xceed
Molecular, Toronto, ON, Canada).
Data normalization
The mean ratio of the intensities of the replicate probes
that were printed on both of the ovarian cancer arrays
212279_at 27346 TMEM97 26
37408_at 9902 MRC2 26
201140_s_at 5878 RAB5C 26
214218_s_at 7503 XIST 24
200600_at 4478 MSN 24
201136_at 5355 PLP2 24
C: Genes exhibiting differential expression profiles based 
on older generation Affymetrix GeneChips (Hs 6000 (6), 
Hu 6800 (22))
202431_s_at 4609 MYC 6
203752_s_at 3727 JUND 6
205009_at 7031 TFF1 6
205067_at 3553 IL1B 6
200807_s_at 3329 HSPD1 6
203139_at 1612 DAPK1 6
200886_s_at 5223 PGAM1 6
203083_at 7058 THBS2 6
202284_s_at 1026 CDKN1A 6
212667_at 6678 SPARC 6
202627_s_at 5054 SERPINE1 6
203382_s_at 348 APOE 6
211300_s_at 7157 TP53 6
200953_s_at 894 CCND2 6
201700_at 896 CCND3 6
205881_at 7625 ZNF74 23
207081_s_at 5297 PI4KA 23
205576_at 3053 SERPIND1 23
203412_at 8216 LZTR1 23
206184_at 1399 CRKL 23
D: Known oncogenes and tumour U133A analysis 
suppressor genes relevant to ovarian cancer biology
203132_at 5925 RB1
204531_s_at 672 BRCA1
214727_at 675 BRCA2
202520_s_at 4292 MLH1
216836_s_at 2064 ERBB2
204009_s_at 3845 KRAS
206044_s_at 673 BRAF
209421_at 4436 MSH2
211450_s_at 2956 MSH6
*GeneID (gene identification number) is based on the nomenclature used in the Entrez Gene database available through the National Center for 
Biotechnology Information (NCBI)
http://www.ncbi.nlm.nih.gov.
Table 1: Selection Criteria of Genes Assayed by Ziplex Technology (Continued)Journal of Translational Medicine 2009, 7:55 http://www.translational-medicine.com/content/7/1/55
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were used to scale the data between the two TipChip
arrays hybridized with each sample. The mean scaling fac-
tor for the 27 samples was 1.03 with a maximum of 1.23.
The coefficients of variation (CV) across 27 samples and
the expression differences between NOSE and TOV sam-
ples was calculated from the raw data for each of the 10
genes included on the arrays as potential normalization
genes (Additional File 2). The geometric means of the sig-
nals for probes for PARK7, PI4KB, TBCB, and UBC with
small CVs (mean of 25%) and insignificant differences
between NOSE and TOV (p > 0.48) were used to normal-
ize the data (refer to Additional File 2 for all normaliza-
tion gene results). The data were analyzed with and
without normalization.
Selection of optimal probe design
The hybridization intensities of the replicate probes
designed for each gene for the 27 samples were compared
to choose a single probe per gene with optimal perform-
ance. This assessment was based on signal intensity (well
above the noise level and within the dynamic range of the
system), minimum distance from the 3' end of the target
sequence and correlation between different probe
designs. Minimum distance from the 3' end is a consider-
ation since the RNA sample preparation process is some-
what biased to the 3' end of the transcripts. The signals for
probes for the same target should vary proportionally
between different samples if both probes bind to and only
to the nominal target. Good correlation between different
Ziplex probe designs for genes in the RefSeq database, as
well as good correlation with the Affymetrix data and dis-
crimination between sample types, infers that probes bind
to the intended target sequences. Data from the chosen
probe was used for all subsequent analysis. Correlations
of signal intensities for pairs of probes for the same genes
are presented in Additional File 3.
Comparative analysis of Ziplex and Affymetrix data
Correlations between Ziplex and Affymetrix array datasets
were calculated. The Affymetrix U133A data was previ-
ously derived from RNA expression analysis of the NOSE
and TOV samples and EOC cell lines. Hybridization and
scanning was performed at the McGill University and
Genome Quebec Innovation Centre http://www.genom
equebecplatforms.com. MAS5.0 software (Affymetrix®
Microarray Suite) was used to quantify gene expression
levels. Data was normalized by multiplying the raw value
for an individual probe set (n = 22,216) by 100 and divid-
ing by the mean of the raw expression values for the given
sample data set, as described previously [23,28]. Affyme-
trix and Ziplex data were matched by gene, and correla-
tions (p < 0.01, using values only of greater than 4) and a
graphical representation was determined using Mathe-
matica (Version 6.03) software (Wolfram Research, Inc.,
Champaign, IL, USA). Mean signal intensity values were
log2 transformed and compared between NOSE and TOV
data using a Welch Rank Sum Test, for both Affymetrix
microarray and Ziplex array data. A p-value of less than
0.001 was used as the significance level.
Composition of mean-difference plots followed the
method of Bland and Altman [29]. Briefly, the mean of
the log2 fold change and the difference between the log2
fold change for the platforms under comparison were cal-
culated and plotted. The 95% limits of agreement were
calculated as follows: log2 fold change difference ± 1.96 ×
standard deviation of the log2 fold change difference.
Quality control of Ziplex array data
The percent CVs were greater for probes with signals
below 30. The overall median of the median probe per-
cent CV was 4.7%. The median of the median percent CVs
was 4.4% for probes with median intensities greater than
30, and 8.0% for probes with median CVs less than or
equal to 30. The signal to noise (SNR) values is the aver-
age of the ratios for the net signals of the replicate spots to
the standard deviation of the pixel values used to evaluate
background levels (an image noise estimate). Average
SNR ranged from -0.3 to 32.8. The signal intensities and
ratios of intensity signals derived from 3' and 5' probes are
shown in Additional File 4. Sample MG0001, which
included many high 3'/5' ratios, was not included for sub-
sequent analysis. The 3'/5' signal intensity ratios corre-
lated with the RIN numbers and 28 S/18 S ratios
(Additional File 5), indicating that, as expected, amplified
RNA fragment lengths vary according to the integrity of
the total RNA sample.
Results
Correlation of Affymetrix U133A and Ziplex array 
expression profiles
Normalized Affymetrix U133A and Ziplex gene expres-
sion data were matched by gene. For each gene expression
platform, values less than 4 were considered to contribute
to censoring bias and were not included in the correlation
analysis. Correlations (log10 transformed) for paired gene
expression data ranged from 0.0277 to 0.998, with an
average correlation of 0.811 between Affymetrix and
Ziplex gene expression data (Additional File 6). For a
detailed summary of the correlation analysis, see also
Additional File 7. The expression profiles of 82 of the 93
(88.2%) genes were significantly positively correlated (p <
0.01) in a comparison of the two platforms. As shown
with the selected examples, genes exhibiting under-
expression, such as ALDH1A3 and CCL2, or over-expres-
sion, such as APOE and EVI1, in the TOV samples relative
to the NOSE samples by Affymetrix U133A microarray
analysis also exhibited similar patterns of expression by
Ziplex array (Figure 1). In contrast, TRAF4 expression was
not correlated between the platforms (R2 = 0.0003). How-Journal of Translational Medicine 2009, 7:55 http://www.translational-medicine.com/content/7/1/55
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ever, both platforms yielded low expression values for this
gene. Although gene expression at very low levels may be
difficult to assay and can be affected by technical variabil-
ity, a good correspondence between platforms can be
achieved with specific probes, as shown in the compari-
son of the BRCA1  expression profiles (R2  = 0.870)
(Figure 1).
Comparative analysis of fold changes of Affymetrix U133A 
and Ziplex array expression profiles
The fold change differences in gene expression were com-
pared between the two platforms. There was a strong cor-
respondence of gene expression patterns across the
platforms when compared for each gene (Table 2). In
terms of overall concordance of statistical significance
between NOSE and TOV samples, there were consistent
results for 75 of 93 genes by Affymetrix and Ziplex analy-
sis (p < 0.001) by Welch rank sum test, in each platform.
The fold change differences were concordant for 87 of 93
(94%) genes where there was agreement between the plat-
forms regarding statistical significance for 71 (76%) of the
87 genes. The fold change differences were discordant for
6 genes, but the differences were statistically insignificant
on both platforms for four of these genes. For example for
the gene SERPIND1, there is no concordance in terms of
fold change between the two platforms, but these fold
change differences are not significant for either platform
(p > 0.001). These results exemplifies that caution should
be used when relying on fold change results alone. Nota-
bly, for two of the discordantly expressed genes (MSH6
and TFF1), the fold change differences were statistically
significant (p < 0.001) only on the Ziplex platform but
not for the Affymetrix platform.
As shown in Figure 2A, there was a strong agreement
between the two platforms as shown by comparisons of
log2 fold differences of gene expression between TOV ver-
sus NOSE samples (R = 0.93) and by Bland-Altman anal-
ysis (Figure 2B), where the majority of probes exhibited
expression profiles in comparative analyses that fell
within the 95% limits of agreement. Both statistical meth-
ods of comparative analysis of log2 fold differences show
minimal variance as the mean increases regardless of the
direction of expression difference evaluated: genes
selected based on over- or under-expression in TOV sam-
ples relative to NOSE samples. Although there were exam-
ples of expression differences which fell outside the 95%
limits of agreement as observed in the Bland-Altman anal-
ysis such as for RGSF4, PDPN, IGKC, IGHG1, C1QTNF1,
TFF1 and IL1B (Figure 2B), both the directionality and
magnitude of TOV versus NOSE expression patterns were
generally consistent (Figure 2A and Table 2).
Discussion
The Ziplex array technology as applied to ovarian cancer
research was capable of reproducing expression profiles of
genes selected based on their Affymetrix GeneChip pat-
terns. A high concordance of gene expression patterns was
evident based on overall correlations, significance testing
and fold-change comparisons derived from both plat-
forms. The Ziplex array technology was validated by test-
ing the expression of genes exhibiting not only significant
differences in expression between normal tissues (NOSE)
and ovarian cancer (TOV) samples but also the vast range
in expression values exhibited by these samples using the
Affymetrix microarray technology. Notable also is that
comparisons were made between Affymetrix GeneChip
data that was derived using MAS5 software rather than
RMA analysis. We have routinely used MAS5 derived data
in order to avoid potential skewing of low and high
expression values which could occur with RMA treated
data sets as this is more amenable to data sets of limited
sample size [6,23,25,26,30]. MAS5 derived data also
allows for exclusion of data that may represent ambiguous
expression values as reflected in a reliability score based
on comparison of hybridization to sets of probes repre-
senting matched and mismatch sequences complemen-
tary to the intended target RNA sequence. A recent study
has re-evaluated the merits of using MAS5 data with detec-
tion call algorithms demonstrating its overall utility [31].
Our results are consistent with a previous study which had
tested the analytical sensitivity, repeatability and differen-
tial expression of the Ziplex technology within a MAQC
study framework [21]. As with all gene expression plat-
forms, reproducibility is more variable within very low
range of gene expression. Gene expression values in the
low range across comparable groups would unlikely be
developed as RNA expression biomarkers at the present
time regardless of platform used. The MAQC study
included a comparison of Xceed Molecular platform per-
formance with at least three major gene expression plat-
forms in current use in the research community, such as
Affymetrix GeneChips, Agilent cDNA arrays, and real-time
RT-PCR. The implementation of some of these various
technology platforms in a clinical setting may require sig-
nificant infrastructure which may be awkward to imple-
ment due to the level of expertise involved. In some cases,
costs may also be prohibitive but this should diminish
over time with increase in usage in clinical settings. It is
also not clear that expression biomarkers are readily
adaptable to all cancer types as this requires sufficient clin-
ical specimens to extract amounts of good quality RNA for
RNA biomarker screening to succeed. Tumor heterogene-
ity is also an issue. The large size and largely tumor cell
composition of ovarian cancer specimens may render this
disease more readily amenable to the development and
implementation of RNA biomarker screening strategies in
order to improve health care of ovarian cancer patients.
The ease with which to use the Ziplex Automated Work-
station focus array and the fact that it appears to perform
overall as well as highly sensitive gene expression technol-
ogies including real-time RT-PCR, suggests that this newJournal of Translational Medicine 2009, 7:55 http://www.translational-medicine.com/content/7/1/55
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Correlation plots of selected genes underexpressed in TOV (A, B), over-expressed in TOV (C, D) and showing low expression  (E, F) across samples Figure 1
Correlation plots of selected genes underexpressed in TOV (A, B), over-expressed in TOV (C, D) and showing 
low expression (E, F) across samples. Xceed Ziplex (XZP) expression data is plotted on the x axis and Affymetrix (AFX) 
microarray data on the y axis. The EOC cell lines are indicated in green (n = 3), TOV samples in red (n = 12) and NOSE sam-
ples in blue (n = 11). Correlation coefficients are shown at the bottom right.
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Table 2: Comparison of mean signal intensity (SI) values for the 93 gene probes between NOSE and TOV samples
Affymetrix U133A Array Ziplex Automated Workstation Platform Comparison
Selection 
Criteria1
Gene Probe NOSE mean 
SI (n = 11)
TOV mean SI 
(n = 12)
ratio (N/T)2 ratio (T/N)2 p-value3 NOSE mean 
SI (n = 11)
TOV mean 
SI (n = 12)
ratio (N/T)2 ratio (T/N)2 p-value3 significance 
based on p-
value3
concordance 
based on ratio 
fold-change 
direction
AR G S 4 2 9 1 2181.2 0.01 <0.0001 863 41 21.1 0.05 <0.0001 agree concordance
C SERPINE1 1912 12 162.4 0.01 <0.0001 1426 17 82.2 0.01 <0.0001 agree concordance
AP D P N 5 7 2 23.9 0.04 0.0008 100 35 2.9 0.35 0.0023 disagree concordance
AA L D H 1 A 3 6 6 1 2 922.6 0.04 0.0020 1887 76 24.8 0.04 0.0051 agree concordance
A IL8 1353 69 19.7 0.05 0.0151 4465 231 19.3 0.05 0.0015 agree concordance
A PTGIS 1470 80 18.4 0.05 <0.0001 3474 184 18.9 0.05 <0.0001 agree concordance
A HEG1 923 66 14.1 0.07 <0.0001 3184 252 12.6 0.08 <0.0001 agree concordance
A TMEM158 461 33 13.9 0.07 <0.0001 869 46 18.8 0.05 <0.0001 agree concordance
C CDKN1A 598 53 11.4 0.09 <0.0001 385 63 6.1 0.16 <0.0001 agree concordance
A CCL2 570 54 10.6 0.09 0.0010 1923 207 9.3 0.11 0.0001 agree concordance
AL X N 7 3 1 7 310.1 0.10 <0.0001 926 124 7.5 0.13 0.0002 agree concordance
CS P A R C1 0 3 71 0 89.6 0.10 <0.0001 2841 341 8.3 0.12 <0.0001 agree concordance
C IL1B 666 70 9.6 0.10 0.0247 1559 46 34.0 0.03 0.0035 agree concordance
A BDKRB1 152 18 8.7 0.11 0.0004 464 22 21.0 0.05 <0.0001 agree concordance
BS L C 1 6 A 3 4 2 5 6 36.8 0.15 <0.0001 197 37 5.3 0.19 <0.0001 agree concordance
AF S T L 1 1 8 3 72 7 76.6 0.15 <0.0001 5293 732 7.2 0.14 <0.0001 agree concordance
CT H B S 2 8 4 6 1 3 56.3 0.16 <0.0001 668 105 6.4 0.16 0.0009 agree concordance
AI G F B P 41 4 8 42 3 86.2 0.16 <0.0001 692 122 5.7 0.18 0.0001 agree concordance
A PTRF 976 168 5.8 0.17 <0.0001 217 77 2.8 0.35 <0.0001 agree concordance
AG B E 1 7 7 5 1 3 65.7 0.18 <0.0001 988 173 5.7 0.17 <0.0001 agree concordance
A PLOD2 654 123 5.3 0.19 <0.0001 926 132 7.0 0.14 <0.0001 agree concordance
AV A T 1 8 7 4 1 7 55.0 0.20 <0.0001 255 78 3.3 0.31 <0.0001 agree concordance
AC O L 1 A 1 2 9 4 06 1 44.8 0.21 0.0001 1502 289 5.2 0.19 0.0003 agree concordance
CC C N D 23 2 4 7 0 4.7 0.21 0.0127 481 117 4.1 0.24 0.0337 agree concordance
A SELT 558 148 3.8 0.27 0.0010 166 137 1.2 0.8 >0.05 disagree concordance
B C1QTNF1 169 48 3.6 0.28 <0.0001 30 3 11.7 0.09 <0.0001 agree concordance
A VGLL3 35 10 3.5 0.29 <0.0001 75 12 6.1 0.16 0.0015 disagree concordance
CP G A M 11 4 8 24 7 33.1 0.32 <0.0001 1603 504 3.2 0.31 <0.0001 agree concordance
CT P 5 3 5 5 1 8 3.0 0.33 0.0178 197 226 0.9 1.1 >0.05 agree discordance
BM S N 7 4 62 5 03.0 0.33 <0.0001 818 354 2.3 0.43 <0.0001 agree concordance
BP S M D 3 1 9 6 6 63.0 0.34 <0.0001 735 384 1.9 0.5 <0.0001 agree concordance
BW S B 1 3 0 01 0 32.9 0.34 0.0003 313 155 2.0 0.50 0.0006 agree concordance
BM R C 2 3 1 31 0 92.9 0.35 <0.0001 528 138 3.8 0.26 <0.0001 agree concordance
A MYH10 1113 420 2.6 0.38 0.0006 1096 464 2.4 0.42 0.0106 disagree concordance
BN S F 1 8 0 7 22.5 0.40 <0.0001 304 170 1.8 0.6 0.0023 disagree concordance
AP 4 H B 2 2 7 69 1 72.5 0.40 <0.0001 4567 1553 2.9 0.34 <0.0001 agree concordance
C SERPIND1 7 3 2.2 0.45 >0.05 79 117 0.7 1.5 0.0363 agree discordance
B RAB5C 309 142 2.2 0.46 0.0106 132 61 2.2 0.46 <0.0001 disagree concordance
BP F N 2 8 0 03 9 22.0 0.49 <0.0001 699 444 1.6 0.6 0.0005 agree concordance
B TRAF4 47 23 2.0 0.50 0.0363 30 27 1.1 0.9 >0.05 agree concordance
B LSM12 59 31 1.9 0.5 0.0023 53 36 1.5 0.7 0.0106 agree concordance
B PLP2 294 157 1.9 0.5 0.0051 270 190 1.4 0.7 0.0151 agree concordance
B PAFAH1B1 181 98 1.9 0.5 0.0006 556 387 1.4 0.7 0.0089 disagree concordance
B TIMM22 42 23 1.8 0.5 0.0392 126 82 1.5 0.6 0.0001 disagree concordance
B AMOTL2 308 173 1.8 0.6 0.0015 776 484 1.6 0.6 0.0113 agree concordanceJ
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B ATP1B3 668 386 1.7 0.6 <0.0001 832 449 1.9 0.5 0.0015 disagree concordance
C DAPK1 181 117 1.5 0.6 >0.05 186 146 1.3 0.8 >0.05 agree concordance
B TFRC 894 606 1.5 0.7 0.0089 386 216 1.8 0.6 0.0062 agree concordance
B ATG3 200 139 1.4 0.7 0.0106 342 319 1.1 0.9 >0.05 agree concordance
B RNF7 177 125 1.4 0.7 0.0178 54 63 0.9 1.2 >0.05 agree concordance
A IL18 21 16 1.4 0.7 0.0148 125 104 1.2 0.8 0.0210 agree concordance
C CRKL 38 28 1.4 0.7 >0.05 18 23 0.8 1.3 >0.05 agree concordance
B XIST 103 76 1.4 0.7 >0.05 256 378 0.7 1.5 >0.05 agree discordance
C PI4KA 59 44 1.4 0.7 0.0127 110 113 1.0 1.0 >0.05 agree concordance
D MSH6 62 47 1.3 0.8 >0.05 227 519 0.4 2.3 0.0010 disagree discordance
C LZTR1 82 69 1.2 0.8 >0.05 81 74 1.1 0.9 >0.05 agree concordance
D MLH1 171 150 1.1 0.9 >0.05 143 150 1.0 1.0 >0.05 agree concordance
C MYC 151 142 1.1 0.9 >0.05 119 212 0.6 1.8 >0.05 agree discordance
B PCOLCE2 22 21 1.0 1.0 >0.05 39 39 1.0 1.0 >0.05 agree concordance
C CCND3 136 139 1.0 1.0 >0.05 101 134 0.7 1.3 0.0127 agree concordance
D KRAS 157 162 1.0 1.0 >0.05 150 200 0.8 1.3 >0.05 agree concordance
A SEPT9 880 918 1.0 1.0 >0.05 543 394 1.4 0.7 >0.05 agree concordance
D RB1 67 73 0.9 1.1 >0.05 166 225 0.7 1.4 >0.05 agree concordance
D BRCA2 10 12 0.8 1.2 >0.05 15 23 0.6 1.6 0.0210 agree concordance
B SNX4 43 52 0.8 1.2 >0.05 199 339 0.6 1.7 0.0042 agree concordance
A BTN3A2 40 48 0.8 1.2 >0.05 89 173 0.5 1.9 0.0005 disagree concordance
C TFF1 12 16 0.7 1.4 >0.05 226 61 3.7 0.3 <0.0001 disagree discordance
B NUP85 71 101 0.7 1.4 >0.05 85 134 0.6 1.6 0.0028 agree concordance
C JUND 759 1181 0.6 1.6 >0.05 1725 2479 0.7 1.4 >0.05 agree concordance
B OSBPL11 46 74 0.6 1.6 0.0151 56 148 0.4 2.6 <0.0001 disagree concordance
D BRCA1 15 24 0.6 1.6 >0.05 27 40 0.7 1.5 >0.05 agree concordance
B SR140 144 243 0.6 1.7 0.0089 13 64 0.2 5.0 <0.0001 disagree concordance
D BRAF 27 46 0.6 1.7 0.0089 22 47 0.5 2.1 <0.0001 disagree concordance
C ZNF74 12 21 0.6 1.8 0.0042 16 44 0.4 2.8 0.0002 disagree concordance
B TOMM70A 212 383 0.6 1.8 0.0004 115 306 0.4 2.7 <0.0001 agree concordance
B RPL24 1895 3503 0.5 1.8 0.0002 1834 4179 0.4 2.3 0.0003 agree concordance
CH S P D 1 8 9 91 6 8 2 0.5 1.9 0.0002 461 1189 0.4 2.6 0.0004 agree concordance
DM S H 2 2 7 5 3 0.5 2.0 0.0023 112 495 0.2 4.4 <0.0001 disagree concordance
BM Y N N 2 7 5 50.5 2.1 0.0001 16 40 0.4 2.5 0.0005 agree concordance
D ERBB2 99 230 0.4 2.3 0.0003 50 142 0.4 2.8 0.0002 agree concordance
BI C A M 2 1 4 3 40.4 2.5 0.0011 13 25 0.5 1.9 0.0089 agree concordance
B CEP70 23 59 0.4 2.6 <0.0001 56 182 0.3 3.3 <0.0001 agree concordance
B TMEM97 70 195 0.4 2.8 0.0015 51 140 0.4 2.8 0.0004 disagree concordance
BC D 3 0 0 A1 1 3 60.3 3.3 <0.0001 43 6 0.1 9.2 0.0006 agree concordance
A STAT1 30 109 0.3 3.6 0.0127 48 110 0.4 2.3 0.0210 agree concordance
AE V I 1 1 1 1 9 7 0.06 17.5 <0.0001 36 636 0.06 17.5 <0.0001 agree concordance
CA P O E 7 1 2 6 0.06 17.9 <0.0001 39 326 0.12 8.4 <0.0001 agree concordance
AC P 7 2 9 5 0.02 43.5 <0.0001 33 972 0.03 29.3 <0.0001 agree concordance
AR G S 1 2 1 1 2 0.02 47.0 <0.0001 31 6 9 0.02 56.5 <0.0001 agree concordance
AS P O N 1 5 2 7 1 0.02 57.8 <0.0001 62 5 7 0.02 44.9 <0.0001 agree concordance
AC D 2 4 6 4 8 1 0.01 77.2 <0.0001 63 3697 0.02 58.5 <0.0001 agree concordance
AI G K C 7 9 9 1 0.01 151.6 <0.0001 27 873 0.03 32.6 0.0008 agree concordance
A IGHG1 3 1262 0.003 374.3 <0.0001 19 203 0.10 10.5 <0.0001 agree concordance
1See Table 1 for description of categories of selection criteria. 2Fold change >2 or <0.5 (bold) between NOSE (N) and TOV (T) gene expression comparison. 3Welch Rank Sum Test p<0.001 
(italics) difference between NOSE (N) and TOV (T). 
Table 2: Comparison of mean signal intensity (SI) values for the 93 gene probes between NOSE and TOV samples (Continued)Journal of Translational Medicine 2009, 7:55 http://www.translational-medicine.com/content/7/1/55
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platform might be amenable to translational research of
gene expression-based biomarkers for ovarian cancer ini-
tially identified from established large-scale gene expres-
sion platforms.
Data normalization of gene expression values is a subject
of intense study and is a major consideration when mov-
ing from one technology platform to another [4,5]. In this
study, data normalization of the Ziplex data was achieved
by using the expression values derived from seven genes,
each of which had low CV values across all samples tested.
Since the input quantity of amplified RNA was equivalent
for all Ziplex arrays, raw data could also have been used in
our analysis. A statistical analysis based on correlations
and fold-changes found negligible differences between
raw and normalized data (not shown). Affymetrix Gene-
Chip and Ziplex systems also differ in a number of techni-
cal ways that may affect the determination of gene
expression. Affymetrix probe design is based on 11 oligo-
nucleotide probes, 25 base pairs in size, within a target
sequence of several hundred base pairs. The gene expres-
sion value is based on the median of the measured signal
from the 11 probes. The probe design for the Ziplex sys-
tem is based on oligonucleotide probes ranging from 35
to 50 bases. In this study three probes were designed and
tested for each target gene and a single optimal probe was
chosen. The visualization system for gene expression dif-
fers for both platforms where expression using the Ziplex
array is measured by chemiluminescence, whereas fluo-
rescence is used for the Affymetrix GeneChip. In spite of
these differences, our findings along with an independent
assessment of the Ziplex system [21] indicated a high
degree of correspondence in expression profiles generated
across both platforms. The overall findings are not sur-
prising given that the probe design was intentionally tar-
geted to similar 3'UTR sequences for the tested gene. Thus,
the overall reproducibility of expression profiles along
with the possibility of using raw data would be an attrac-
tive feature of applying the Ziplex system to validated
biomarkers that were discovered using the Affymetrix
platform.
The expression patterns of many of the tested genes were
previously validated by an independent technique from
our research group. RT-PCR analyses of ovarian cancer
samples validated gene expression profiles of TMEM158,
GBE1  and HEG1  from a chromosome 3 transcriptome
analysis [25] and IGFBP4, PTRF and C1QTNF1 from a
chromosome 17 transcriptome analysis [26]. The Ziplex
platform also revealed over-expression of genes (ZNF74,
PIK4CA, SERPIND1, LZTR1 and CRKL) associated with a
chromosome 22q11 amplicon found in the OV90 EOC
cell line and initially characterized by earlier generation
Affymetrix expression microarrays and validated by RT-
PCR and Northern blot analysis [23]. Differential expres-
Comparison of the fold change difference in expression  between NOSE and TOV samples for the Ziplex and Affyme- trix platforms Figure 2
Comparison of the fold change difference in expres-
sion between NOSE and TOV samples for the Ziplex 
and Affymetrix platforms. A: The log2 fold change 
between the NOSE and TOV samples (mean NOSE signal 
intensity/mean TOV signal intensity) was calculated for the 
expression values of all 93 probes and plotted. Linear regres-
sion was performed resulting in the following model: log2 
Affymetrix NOSE/TOV = 0.180098 + 1.0251794 log2 Ziplex 
NOSE/TOV with a Pearson's correlation coefficient (R) of 
0.93. Probes that were not significant (p > 0.001 based on a 
Welch Rank Sum test) on either platform are indicated in 
grey, probes significant (p < 0.001 based on a Welch Rank 
Sum test) on both platforms are indicated in black, on only 
the Ziplex platform are indicated in blue and on only the 
Affymetrix platform in green. B: Bland-Altman plots for 
expression values of all probes. Values determined to be out-
liers are indicated in the mean-difference (of the log2 fold 
change values) plot. A difference in log2 fold change of 0 is 
indicated by a solid black line. The upper and lower 95% lim-
its of agreement for the difference in log2 fold change are 
indicated by red dashed lines, and arrows on the right hand 
side. Expression values that fall outside of these lines are 
considered outliers and are identified by their gene name.
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sion of SPARC, a tumor suppressor gene implicated in
ovarian cancer, has been shown to give consistent expres-
sion profiles in EOC cell lines and samples across a
number of Affymetrix GeneChip® platforms and by RT-
PCR from our group and others [6,30,32]. This indicates
the utility of using older generation Affymetrix GeneChip
data where good concordance can be observed with his-
torical data and the accuracy of the earlier generation
GeneChips has been evaluated by alternative techniques
in the literature [6,23]. This is an important consideration
particularly given the large number of historical data sets
that are available for further mining of potential gene
expression biomarkers. Northern blot analysis has vali-
dated expression of MYC,  HSPD1,  TP53  and  PGAM1
which were initially found to be differentially expressed in
our EOC cell lines by the prototype Affymetrix GeneChip
[6]. Concordance of gene expression was also evident
from the 10 genes (see Table 1) selected based on an
Affymetrix U133A microarray analysis of TOV samples
and short term cultures of NOSE samples reported by an
independent group [3]. BTF4  is a potential prognostic
marker for ovarian cancer and was originally identified by
Affymetrix microarray technology and then validated by
real-time RT-PCR analysis [14]. Assaying the expression of
BTF4 in clinical specimens is of particular interest because
at the time of study there was no available antibody, illus-
trating the need for a reliable and accurate quantitative
gene expression platform for RNA molecular markers.
Conclusion
It is becoming increasingly apparent that expression sig-
natures involving multiple genes can be correlated with
various clinical parameters of disease, and in turn that
these signatures could be used as biomarkers [4,5].
Although the expression signatures are gleaned from the
statistical analyses of transcriptomes from genome-wide
expression analyses, such as with use of Affymetrix Gene-
Chip, the use of such arrays requires technical expertise
and infrastructure that is not at the present time readily
adaptable to clinical laboratories. In this study we have
shown the concordance of the expression signatures
derived from Affymetrix microarray analysis by the Ziplex
array technology, suggesting that it is amenable for trans-
lational research of expression signature biomarkers for
ovarian cancer.
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